13698 related articles for article (PubMed ID: 10470104)
1. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Schultz RM; Merriman RL; Andis SL; Bonjouklian R; Grindey GB; Rutherford PG; Gallegos A; Massey K; Powis G
Anticancer Res; 1995; 15(4):1135-9. PubMed ID: 7653991
[TBL] [Abstract][Full Text] [Related]
3. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model.
Davol P; Frackelton AR
J Urol; 1996 Sep; 156(3):1174-9. PubMed ID: 8709341
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of basic FGF and heparin binding EGF conjugated with cytotoxin saporin on vascular cell cultures.
Chen C; Li J; Micko CJ; Pierce GF; Cunningham MR; Lumsden AB
J Surg Res; 1998 Feb; 75(1):35-41. PubMed ID: 9614854
[TBL] [Abstract][Full Text] [Related]
5. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model.
Davol P; Beitz JG; Mohler M; Ying W; Cook J; Lappi DA; Frackelton AR
Cancer; 1995 Jul; 76(1):79-85. PubMed ID: 8630880
[TBL] [Abstract][Full Text] [Related]
6. Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
Davol PA; Garza S; Frackelton AR
Cancer; 1999 Nov; 86(9):1733-41. PubMed ID: 10547546
[TBL] [Abstract][Full Text] [Related]
7. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance.
Davol PA; Frackelton AR
Prostate; 1999 Aug; 40(3):178-91. PubMed ID: 10398280
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo.
Beitz JG; Davol P; Clark JW; Kato J; Medina M; Frackelton AR; Lappi DA; Baird A; Calabresi P
Cancer Res; 1992 Jan; 52(1):227-30. PubMed ID: 1309225
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
Wang Q; Li N; Wang X; Kim MM; Evers BM
Clin Cancer Res; 2002 Jun; 8(6):1940-7. PubMed ID: 12060639
[TBL] [Abstract][Full Text] [Related]
11. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus infection enhances killing of melanoma cells by a mitotoxin.
Satyamoorthy K; Soballe PW; Soans F; Herlyn M
Cancer Res; 1997 May; 57(10):1873-6. PubMed ID: 9157978
[TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.
Norman BH; Shih C; Toth JE; Ray JE; Dodge JA; Johnson DW; Rutherford PG; Schultz RM; Worzalla JF; Vlahos CJ
J Med Chem; 1996 Mar; 39(5):1106-11. PubMed ID: 8676346
[TBL] [Abstract][Full Text] [Related]
14. Biphasic effect of the mitotoxin bFGF-saporin on bovine lens epithelial cell growth: effect of cell density and extracellular matrix.
David T; Tassin J; Lappi DA; Baird A; Courtois Y
J Cell Physiol; 1992 Dec; 153(3):483-90. PubMed ID: 1447311
[TBL] [Abstract][Full Text] [Related]
15. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
17. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.
Price BD; Youmell MB
Cancer Res; 1996 Jan; 56(2):246-50. PubMed ID: 8542574
[TBL] [Abstract][Full Text] [Related]
18. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo.
Stojkovic R; Karminski-Zamola G; Racane L; Tralic-Kulenovic V; Glavas-Obrovac L; Ivankovic S; Radacic M
Methods Find Exp Clin Pharmacol; 2006; 28(6):347-54. PubMed ID: 16894403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
